This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Menkes disease (kinky hair disease, disorders of copper metabolism)Menkes Disease (Kinky Hair Disease / Disorders of Copper Metabolism)

ItemDetails
A. Classification codesICD-10: E83.0 (disorders of copper metabolism) | Special Copayment Reduction: V119
B. SynonymsMenkes (kinky hair) (steely hair) disease, copper-deficiency neurodegenerative disease, Steely hair syndrome, Kinky hair disease, disorders of copper metabolism (including the general E83.0 category); mild variant: Occipital horn syndrome
C. Adult onsetLikelihood of first presentation in adulthood very low — classic Menkes disease presents at 2–3 months of age with neurologic regression and characteristic hair changes. However, the mild spectrum caused by ATP7A variants (occipital horn syndrome, asymptomatic MEDNIK-like presentation) is sometimes first diagnosed in adolescence or adulthood with connective tissue abnormalities and neurologic symptoms.
1. HistoryFirst described by Menkes in 1962; copper deficiency mechanism confirmed in 1972; ATP7A gene identified in 1993
2. CausesATP7A gene variants → loss of function of the copper-transporting ATPase (ATP7A) → impaired intestinal copper absorption and systemic copper deficiency
3. GeneticsX-linked recessive; ATP7A (Xq21.1); almost all patients are male; diverse phenotypic spectrum
4. EpidemiologyAbout 1 per 100,000–300,000 births; more than 300–400 cases registered worldwide
5. PathophysiologyATP7A deficiency → copper accumulation in enterocytes and reduced blood copper → dysfunction of multiple copper-dependent enzymes → neurodegeneration and connective tissue abnormalities
6. SymptomsProgressive neurodegeneration, intractable epilepsy, hypothermia, growth failure, connective tissue abnormalities (skin laxity, joint hypermobility)
7. SignsCharacteristic kinky hair (pili torti), sagging skin, vascular tortuosity, bone changes, infantile hypothermia
8. ScreeningMeasurement of serum copper and ceruloplasmin; plasma catecholamine ratio (DOPA/DHPG); newborn screening research
9. DiagnosisLow serum copper and ceruloplasmin; ATP7A molecular genetic testing; hair microscopy; brain MRI
10. TreatmentCopper histidine subcutaneous injection (most effective when started within 25–28 days of birth); symptomatic treatment
11. PrognosisWithout treatment, most die within 3 years of birth; some improvement in neurodevelopment reported with early treatment within 1 month of birth
12. PreventionGenetic counseling for X-linked recessive carrier females; prenatal diagnosis; early newborn screening (copper and ceruloplasmin testing)
13. ReferencesList of key PMIDs and DOIs

1. History

Menkes disease was first described in 1962 by the American pediatric neurologist John H. Menkes as a fatal disorder in five boys of an Irish-descent family showing progressive neurodegeneration, growth failure and distinctive steely hair. At the time the cause of the metabolic abnormality was unknown, but in 1972 Danks and colleagues found that the serum copper and ceruloplasmin levels of these patients were markedly low and confirmed that intestinal copper absorption was blocked, revealing a defect of copper metabolism as the cause. Then in 1993, three research teams independently identified the ATP7A gene, establishing deficiency of a copper-transporting P-type ATPase as the molecular mechanism of Menkes disease. A mild phenotype caused by partial-function ATP7A variants, occipital horn syndrome, was also recognized as a separate clinical entity after 1975, and these are now classified together as the spectrum of ATP7A-related copper transport disorders. In terms of treatment, copper-histidine subcutaneous injection therapy, tried since the 1970s, is the most widely used treatment. ICD-10 E83.0 is a category covering all disorders of copper metabolism, with Menkes disease (ATP7A deficiency) and Wilson disease (ATP7B deficiency) as representative diseases.

2. Causes

The direct cause of Menkes disease is loss of function of the copper-transporting ATPase (ATP7A, copper-transporting P-type ATPase alpha) due to pathogenic variants in the ATP7A gene located on the X chromosome at Xq21.1. The ATP7A protein mainly transports intracellular copper into the blood at the basolateral membrane of small intestinal epithelial cells, and in many tissues, including the brain, kidney and muscle, it also carries copper to intracellular organelles and out of the cell. When ATP7A function is lost, copper accumulates in small intestinal epithelial cells and copper transport into the blood is blocked, so blood copper and ceruloplasmin are markedly reduced. Copper is a cofactor of dozens of essential enzymes, including cytochrome c oxidase (energy metabolism), dopamine-beta-hydroxylase (catecholamine synthesis), lysyl oxidase (connective tissue cross-linking), superoxide dismutase (defense against oxidative stress) and tyrosinase (melanin synthesis), so copper deficiency leads to dysfunction of all these enzymes and causes multisystem damage. There are no environmental causes; it is a purely genetic disease.

3. Genetics

Menkes disease follows an X-linked recessive mode of inheritance. The causative gene ATP7A is located at Xq21.1 and consists of 23 exons. Because it is X-linked recessive, almost all patients are male (46,XY). Carrier females (heterozygotes) are generally asymptomatic, and mild neurologic symptoms or hair abnormalities may be observed only when X-inactivation is extremely skewed. Variant types are very diverse, including missense, nonsense, splice site, small deletions/insertions and large gene rearrangements (deletions, duplications). About 15–20% of variants arise as new (de novo) mutations without a family history. The clinical phenotypic spectrum varies with the residual function of the ATP7A variant: complete loss of function → classic Menkes disease (severe, early death), partial residual function → occipital horn syndrome (mild, survival into adulthood possible), and intermediate phenotypes. Genetic testing and carrier confirmation are performed with next-generation sequencing (NGS) panels or whole-exome analysis. Confirmation of large deletions/duplications requires array comparative genomic hybridization (Array CGH) or MLPA.

4. General epidemiology

The incidence of Menkes disease is reported as about 1 per 100,000–300,000 births, with some regional variation. The cumulative number of registered patients worldwide is more than 300–400 cases, making it particularly uncommon even among rare diseases. Because of its X-linked recessive nature, occurrence is limited to males (female patients are extremely rare and have been reported only in females with chromosomal abnormalities). It occurs in all races, and no founder effect in a specific ethnic group has been reported. Data on the exact prevalence in Asia, including Korea, are very limited, and there are few registered patients in Korea. If occipital horn syndrome is included, the overall frequency of ATP7A-related copper transport disorders may be somewhat higher. Some studies that performed copper and ceruloplasmin screening in the neonatal period suggest that the actual frequency may be higher than previous estimates. Screening studies using measurement of the neonatal plasma catecholamine ratio (DOPA/DHPG) are under way to raise the early diagnosis rate.

5. Pathophysiology

When loss of ATP7A function blocks copper transport from small intestinal epithelial cells into the blood, ingested copper is trapped in enterocytes and blood copper and ceruloplasmin levels are markedly reduced. Copper is a cofactor of dozens of essential metalloenzymes, and its deficiency causes the following multisystem dysfunction.

Neurodegeneration: reduced cytochrome c oxidase function causes impaired mitochondrial energy metabolism and oxidative stress, leading to neuronal death. Reduced dopamine-beta-hydroxylase function decreases norepinephrine synthesis, causing autonomic and catecholamine regulation abnormalities (this is used for diagnosis as an elevated plasma DOPA/DHPG ratio).

Connective tissue abnormalities: reduced lysyl oxidase function impairs cross-link formation of collagen and elastin, making connective tissue fragile. Skin laxity, joint hypermobility, vascular tortuosity, bladder diverticula and others result.

Hair abnormalities: dysfunction of lysyl oxidase and tyrosinase makes keratin cross-linking in hair incomplete, producing distinctive hair structure abnormalities such as pili torti (twisted hair), trichorrhexis nodosa (nodular hair breakage) and monilethrix.

6. Symptoms

Initial symptoms (2–3 months of age): hypotonia, feeding difficulties, poor weight gain and abnormal temperature regulation (hypothermia) appear. Because there are no specific symptoms at birth, early diagnosis is difficult.

Neurologic symptoms: progressive neurodegeneration, intractable epilepsy (including infantile spasms), dystonia and spasticity develop. Developmental milestones are not achieved or already acquired development regresses.

Hair abnormalities: after several weeks to months of age, characteristic twisted hair (pili torti) and a steely hair pattern appear; scalp hair is sparse, light-colored and abnormally twisted. The eyebrows are also affected.

Connective tissue symptoms: the skin sags and loses elasticity, and the joints are excessively flexible. Bladder diverticula, hernias and vascular structural abnormalities may occur.

Vascular complications: tortuous arteries (arterial tortuosity) can lead to subdural hematoma, cerebral infarction and others.

7. Signs

The main signs on physical examination are as follows.

Pili torti (twisted hair): observation of the hair under a microscope or magnifier shows the characteristic form twisted 180 degrees around the long axis (pili torti), nodes (trichorrhexis nodosa) and beading (monilethrix). Light-colored, coarse, twisted hair can be observed even with the naked eye.

Skin and connective tissue: sagging skin, reduced elasticity and tissue laxity on dermatologic examination are confirmed. Joint hypermobility is present.

Neurologic signs: hypotonia, decreased or increased deep tendon reflexes (depending on lesion location), intermittent seizures and developmental regression are confirmed on neurologic examination.

Brain MRI findings: cerebral atrophy, white matter signal abnormalities, subdural hematoma and tortuous cerebral vessels (vascular tortuosity) are observed.

Blood tests: markedly low serum copper (10–30% of normal); markedly low ceruloplasmin; elevated plasma catecholamine DOPA/DHPG ratio; elevated plasma DOPA, low norepinephrine.

8. Screening

Menkes disease is not currently included in standard newborn screening, but several early diagnostic methods are being studied. Measurement of serum copper and ceruloplasmin is the simplest screening method, but because copper may be physiologically low in the early neonatal period (1–2 weeks after birth), care is needed in interpretation. The plasma catecholamine ratio (DOPA/DHPG ratio, dopamine/dihydroxyphenylglycol ratio) reflects reduced dopamine-beta-hydroxylase activity and is markedly elevated in Menkes disease, and it is being studied as a useful biomarker for early diagnosis within the first few weeks of life. Pilot studies applying catecholamine measurement using dried blood spots (DBS) or multi-biomarker testing to newborn screening are under way. In high-risk families (confirmed families, carrier females), early diagnosis is possible with early neonatal blood testing. Hair microscopy is a noninvasive screening method that can be performed rapidly in clinically suspected patients.

9. Diagnosis

Biochemical tests: serum copper and ceruloplasmin are confirmed to be markedly lower than age-based normal values (serum copper <0.3 µmol/L, ceruloplasmin <0.05 g/L). Plasma catecholamine fractions (increased DOPA, decreased dihydroxyphenylglycol, markedly elevated DOPA/DHPG ratio) are a specific biomarker that helps confirm the diagnosis.

Hair examination: characteristic structural abnormalities such as pili torti, trichorrhexis nodosa and monilethrix are confirmed by light or electron microscopy.

Molecular genetic testing: pathogenic variants are confirmed by sequencing of all ATP7A exons and testing for large deletions/duplications (MLPA, Array CGH). It is also used to confirm the diagnosis in newborns or carrier families.

Brain MRI: brain atrophy, white matter abnormalities, subdural hematoma and tortuous cerebral vessels are confirmed.

Skeletal X-ray: occipital process calcification (occipital horn syndrome), osteoporosis, metaphyseal wedge changes and others are confirmed.

Prenatal diagnosis: in pregnancies of carrier females, it is possible through ATP7A gene analysis of chorionic villus samples or amniotic fluid cells and measurement of copper accumulation (measurement of copper content in cultured fibroblasts).

10. Treatment

Copper-histidine subcutaneous injection: currently the most effective specific treatment available for Menkes disease. Copper histidine is given by subcutaneous injection twice daily to replenish blood copper levels. The effect of this treatment depends critically on when treatment is started; there are reports that when started within 25–28 days of birth (neonatal period), some neurodevelopmental function can be maintained or improved. However, when treatment is started after symptom onset, it is difficult to completely halt neurodegeneration. The main limitation is that its low blood-brain barrier (BBB) penetration does not fully correct copper deficiency in the central nervous system.

Symptomatic treatment: anticonvulsants (seizure control), nutritional support (tube feeding, gastrostomy), physical and occupational therapy and respiratory support are needed. When vascular complications (subdural hematoma, etc.) occur, neurosurgical intervention may be required.

Research on new treatments: pharmacological chaperones, gene therapy, mRNA therapy and others are being studied at the preclinical and early clinical stages.

11. Prognosis

The prognosis of classic Menkes disease is very poor. Most untreated patients die within 2–3 years of birth due to progressive neurodegeneration, intractable epilepsy and infectious complications. Survival beyond 5 years of age is rare. Partial preservation of neurodevelopment and extended life expectancy have been reported in some patients who started copper-histidine treatment within 1 month of birth, but outcomes vary greatly between individuals, and complete normalization of neurodevelopment has not been achieved to date. Occipital horn syndrome, the mild phenotype, has a relatively favorable prognosis with survival into adulthood and mainly connective tissue abnormalities and mild neurologic symptoms. Introduction of newborn screening and development of early treatment protocols to improve treatment efficacy are under way. Collaboration with a palliative care team to support caregivers and families is important.

12. Prevention

Complete prevention of Menkes disease is not possible, but carrier screening and prenatal diagnosis based on its X-linked recessive inheritance help prevent the birth of affected newborns. Because the mother of a confirmed patient is a carrier female, carrier status is confirmed by ATP7A variant analysis before the next pregnancy and genetic counseling is provided. When the mother is a carrier, affected male fetuses can be identified early through prenatal diagnosis (ATP7A analysis of chorionic villus samples or amniotic fluid cells). Transferring only unaffected embryos through preimplantation genetic testing (PGT-M) is also possible. Carrier testing is performed in the sisters and maternal relatives of confirmed patients. The goal is to improve neurologic prognosis by diagnosing before symptom onset through expansion of newborn screening programs and starting copper-histidine treatment immediately.

13. References

  1. Menkes JH, et al. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics. 1962;29:764-779. PMID: 14472668
  2. Danks DM, et al. Menkes's kinky hair syndrome. An inherited defect in copper absorption with widespread effects. Pediatrics. 1972;50(2):188-201. PMID: 4560985
  3. Mercer JF, et al. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet. 1993;3(1):20-25. PMID: 8490648
  4. Kaler SG. ATP7A-related copper transport diseases-emerging concepts and future trends. Nat Rev Neurol. 2011;7(1):15-29. PMID: 21221114
  5. Tumer Z. An overview and update of ATP7A mutations leading to Menkes disease and occipital horn syndrome. Hum Mutat. 2013;34(3):417-429. PMID: 23281160
  6. Møller LB, et al. Clinical expression of Menkes disease in females with normal karyotype. Orphanet J Rare Dis. 2012;7:6. PMID: 22264417
  7. Kaler SG, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008;358(6):605-614. PMID: 18256340
  8. Tang J, et al. Emergence of kinky hair in Menkes disease. Neurol Genet. 2024;10(3):e200153. PMID: 38737541
  9. Verrotti A, et al. Menkes disease: clinical, neurological, and treatment aspects. Acta Paediatr. 2014;103(10):1014-1020. PMID: 24965050
  10. Donsante A, et al. ATP7A-Related Copper Transport Disorders. In: Adam MP, et al., eds. GeneReviews®. Seattle: University of Washington; 2016. NBK1413